Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases

Jonathan Feld, Lewis R. Silverman, Shyamala C. Navada

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Advancements in the understanding of the pathogenesis of acute myeloid leukemia (AML) have led to the introduction and approval of a number of novel drugs in AML. Glasdegib, an oral hedgehog pathway inhibitor, was approved in 2018 in combination with low-dose cytarabine for the treatment of newly diagnosed AML in patients unfit for intensive chemotherapy. In this review, we discuss the preclinical rationale for glasdegib, important clinical trials that led to glasdegib's approval, and future trials of glasdegib in AML and other myeloid diseases. Notably, 2 large randomized, placebo-controlled phase 3 trials (AML BRIGHT 1019) are currently recruiting patients with newly diagnosed AML to evaluate glasdegib in combination with intensive chemotherapy or azacitidine, depending on the patient's ability to tolerate induction chemotherapy. While glasdegib and low-dose cytarabine have been eclipsed by venetoclax and hypomethylating agent combinations for newly diagnosed AML in the United States, we discuss other areas where glasdegib may still have an opportunity to improve outcomes in this devastating disease.

Original languageEnglish
Pages (from-to)e415-e422
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number4
StatePublished - Apr 2021


  • Allogeneic stem cell transplant
  • Hedgehog pathway
  • Leukemia stem cells
  • Myelodysplastic syndromes
  • Myelofibrosis


Dive into the research topics of 'Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases'. Together they form a unique fingerprint.

Cite this